Muvalaplin + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Elevated Lp(a)
Conditions
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Trial Timeline
Sep 2, 2025 → Mar 1, 2031
NCT ID
NCT07157774About Muvalaplin + Placebo
Muvalaplin + Placebo is a phase 3 stage product being developed by Eli Lilly for Elevated Lp(a). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07157774. Target conditions include Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07157774 | Phase 3 | Recruiting |
Competing Products
12 competing products in Elevated Lp(a)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Baricitinib | Eli Lilly | Pre-clinical | 23 |
| Rosuvastatin | AstraZeneca | Phase 3 | 77 |
| TQJ230 + Placebo | Novartis | Phase 3 | 77 |
| LIK066 + Placebo | Novartis | Phase 2 | 52 |
| Olpasiran | Amgen | Phase 1 | 32 |
| Maridebart cafraglutide + Placebo | Amgen | Phase 2 | 51 |
| Ivabradine | Amgen | Phase 3 | 76 |
| ALN-PCS02 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 30 |
| ISIS-APO(a)Rx + Placebo | Ionis Pharmaceuticals | Phase 2 | 49 |
| APOC-III-L-Rx + Placebo Comparator | Ionis Pharmaceuticals | Phase 1 | 30 |
| ISIS 681257 + Placebo | Ionis Pharmaceuticals | Phase 2 | 49 |
| IONIS-APO(a)-LRx + Sterile Normal Saline (0.9% NaCl) | Ionis Pharmaceuticals | Phase 1 | 30 |